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Abstract
Background: Recently, it has been demonstrated that, in patients down-regulated by GnRH
analogues (GnRHa), a short-term pre-treatment with recombinant LH (rLH), prior to recombinant
FSH (rFSH) administration, increases the number of small antral follicle prior to FSH stimulation
and the yield of normally fertilized embryos. However, no data exist in the literature regarding the
potential beneficial effect of "hCG priming" in controlled ovarian hyperstimulation (COH) through
a long GnRH-a protocol, which binds the same receptor (LH/hCGR), though it is a much more
potent compared to LH. The primary aims of this study were to assess the effect of short-term
pre-rFSH administration of hCG in women entering an ICSI treatment cycle on follicular
development, quality of oocytes and early embryo development. The secondary endpoints were to
record the effects on endometrial quality and pregnancy rate.
Methods: Patients with a history of at least one previous unsuccessful ICSI cycle were randomly
assigned into two groups to receive treatment with either a long protocol with rFSH (control
group) or a long protocol with rFSH and pre-treatment with hCG (hCG group). In particular, in
the latter group, a fixed 7 days course of 200 IU/day hCG was administered as soon as pituitary
desensitization was confirmed.
Results: The mean number of oocytes retrieved was not significantly different between the two
treatment groups, although the percentage of mature oocytes tended to be higher but not
significantly different in hCG-treated patients. The percentage of patients with more than one grade
3 embryos was higher in the pre-treatment group, which also showed a higher pregnancy rate.
Conclusion: All the above clinical observations, in conjunction with previous data, suggest a point
towards a beneficial "hCG priming" effect in controlled ovarian hyperstimulation through a long
GnRH-a down-regulation protocol, particularly in patients with previous ART failures.
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Background
Ovarian response to gonadotrophins varies considerably
among women. The importance of this differential
response in women with previous ART (IVF/ICSI) failures
has prompted researchers to investigate and determine the
factors that are implicated [1].
Though, follicular development up to the preantral stage
is feasible in the absence of LH, an essential role for this
gonadotrophin for antral formation as well as further
growth and differentiation has been uniformly recog-
nized. LH plays a key role in both oocyte and follicular
cells development through modification of the steroid
and protein micro- and macroenvironment [2,3]. These
physiologic changes have a prominent role in oocyte,
maturation, the process of ovulation, and subsequent fer-
tilization and implantation [4].
It is well known that LH acts synergistically with FSH in
the process of follicular growth: FSH plays a crucial role in
recruitment, selection and dominance, while LH contrib-
utes to dominance maturation and ovulation [2,5]. More-
over, studies in non-human primates have shown that LH
may act by increasing intra-ovarian androgens, which in
turn promote FSH responsive granulosa cell function [6].
Recently, it has been demonstrated that, in patients down-
regulated by GnRH analogues (GnRHa), a short-term pre-
treatment with recombinant LH (rLH), prior to recom-
binant FSH (rFSH) administration, increases the number
of small antral follicles prior to FSH stimulation and the
yield of normally fertilized (2PN) embryos[7]. In addi-
tion, rLH pre-treatment may have a modest impact on
subsequent ovarian responsiveness to FSH. LH activity,
administered as a single dose of hCG in combination with
aromatase inhibitor in early-follicular-phase GnRH-
antagonist protocol has been shown to result in androgen
priming and subsequent increase in the number of good
quality embryos [3]. However, no data exist in the litera-
ture regarding the potential beneficial effect of "hCG
priming" in controlled ovarian hyperstimulation (COH)
through a long GnRH-a protocol, given that hCG occupies
the same receptor (LH/hCGR) though it is much more
potent than LH.
The ideal LH activity, administered as hMG, rLH or hCG
in ART procedures, has not been determined yet. Serum
LH levels of less than 1.5 IU/L have been proven insuffi-
cient to maintain aromatase activity and E2 production
[8]. Low peri-ovulatory levels (<3 IU/L) in patients under-
going IVF are associated with impaired fertilization and
increased early pregnancy loss [9,10]. On the other hand,
small doses of LH administered in early follicular phase
during ovarian stimulation in IVF-ET cycles have a benefi-
cial effect in the quality of oocytes, a fact of utmost impor-
tance, especially in cases where few embryos are available
for transfer [11]. Actually, in poor responders, early LH
administration during COH may have a beneficial effect
on the maturity and fertilizability of oocytes, as well as the
number of transferable embryos [5,12,13]. However,
combined LH and FSH activity administration did not
yield increased pregnancy rates [14,15]. In a recent meta-
analysis of several randomized controlled trials, investi-
gating the effect of rFSH alone or in combination with rLH
in IVF/ICSI cycles, no evidence of a statistical difference
regarding pregnancy outcome in patients where rLH was
used was observed [16].
In common practice, human chorionic gonadotrophin
(hCG) is used as a substitute for the mid-cycle LH surge,
due to the degree of homology between the two hor-
mones [17]. hCG has long been associated with the initi-
ation and maintenance of pregnancy. A potential role for
hCG has been suggested lately in the processes associated
with infertility [18-22]. Although the two molecules have
the same natural function, causing luteinization and sup-
porting lutein cells, hCG has a slower plasma metabolic
clearance, which consists of a rapid phase in the first 5-9
h following IM administration and a slower phase in the
first 1-1.3 days after administration. Both LH and hCG are
complex heterodimeric glycoproteins with different
molecular weights (30 KD and 40 KD respectively). Dif-
ference in their carbohydrate moiety possibly explains dif-
ferent affinity to the LH/hCG receptor and therefore
differentiated function [23,24]. In the absence of FSH,
low-dose hCG can support development and maturation
of larger ovarian follicles (≥15 mm in diameter) that have
acquired granulosa cell LH/hCG receptors and hasten the
demise of smaller follicles lacking these receptors thus
being dependent on FSH stimulation [19,25,26]. Inas-
much as the development of small preovulatory follicles
is associated with increasing rates of ovarian hyperstimu-
lation syndrome, the addition of low dose hCG might
provide effective and safer ovulation induction regimens
[19,25,27]. Moreover, hCG seems to be capable of posi-
tively affecting uterine receptivity by enhancing endome-
trial quality and stromal fibroblast function. In particular,
hCG may improve intrauterine environment and extend
implantation window thus increasing pregnancy rate
through its actions on insulin-like growth factor binding
protein-1 (IGFBP-1) and vascular endothelial growth fac-
tor (VEGF) [11,25,28].
The primary aims of this study were to assess the effect of
short-term pre-rFSH administration of hCG in women
entering an ICSI treatment cycle on follicular develop-
ment, quality of oocytes and early embryo development.
The secondary endpoints were to record the effects on
endometrial quality and pregnancy rate.Reproductive Biology and Endocrinology 2009, 7:91 http://www.rbej.com/content/7/1/91
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Methods
Patient population
Fifty patients with a history of at least one previous unsuc-
cessful ICSI cycle were enrolled into this prospective ran-
domized pilot study. The inclusion criteria were pre-
menopausal woman, 25-40 years of age and a normal
hormonal profile (according to WHO guidelines). None
of the patients had received ovulation induction or any
other hormone treatment for at least three months pre-
ceeding the study.
The patients were randomly assigned into two groups:
Group 1 underwent a long protocol with rFSH (Control
Group) and Group 2 received a long protocol with rFSH
and pre-treatment with hCG (hCG Group). To perform
randomization a random number generator http://
www.random.org was used. For each patient, a random
number between 1 and 100,000 was generated and the
patient was allocated to the corresponding group (Group
1 for odd numbers and Group 2 for even numbers).
The demographic data (age, duration of infertility, previ-
ous attempts, weight and height) for all patients was col-
lected and their BMI was calculated. Cycle day 2 FSH, LH
and PRL were measured prior to the ICSI cycle within the
previous six months.
Ovulation induction
The protocol was approved by our Ethics Committee and
an informed consent was provided by all participants,
according to the Helsinki Declaration. The stimulation
protocol was briefly as follows: on day 21 of the previous
cycle, a baseline ultrasound scan was performed and
buserelin intranasal spray (Superfact; Hoechst, Frankfurt,
Germany) was commenced at a dose of 100 μg five times
daily (every 4 h, omitting the 3.00 a.m. dose) for 14 days.
In all of the patients, the extent of ovarian suppression
was evaluated by both ultrasound scan (absence of ovar-
ian activity, ovarian cyst formation and endometrial pro-
liferation) and serum E2  levels (≤ 40 pg/ml) before
starting exogenous gonadotrophin administration. If the
above criteria were not met, downregulation was
extended for a further week. Group 2 patients were pre-
treated for seven days with 200 IU/day of hCG (Pregnyl;
N.V. Organon, Oss, Netherlands) when ovarian suppres-
sion had occurred. Stimulation was commenced with
rFSH (Gonal-F; Serono, Geneva, Switzerland) at a fixed
dose of 200 IU daily in both groups.
Plasma E2 levels were measured five days after starting
rFSH and then daily from day 8. The first scan was per-
formed on day 9 and subsequent scans were performed
every day.
The dose of rFSH was adjusted according to ovarian
response after 5 days of rFSH administration. GnRHa
administration was continued until hCG administration
for triggering ovulation. In particular, 10,000 IU were
given intramuscularly when the mean diameter of at least
two leading follicles was >18 mm and serum E2 was rising.
The interval between the last gonadotrophin injection and
hCG administration was no more than 24 h. Thirty-five to
36 h after hCG administration, ovum retrieval was per-
formed by transvaginal echo-guided ovarian puncture.
After stripping, oocytes were assessed for their maturation
and only oocytes having resumed their first meiotic divi-
sion reaching metaphase II were used for ICSI.
The embryos were graded according to their morphologic
appearance on a scale from 3 (the best) to 1 under a light
microscope on the day of transfer [29]. Two to three
embryos were transferred according to embryo quality
assessment. Luteal phase was supported with 2,500 IU of
hCG injected on the days of embryo transfer and day 4
after replacement. Serum hCG was measured 14 days after
oocyte retrieval. Clinical pregnancy was confirmed by a
gestational sac with fetal heartbeat movement seen on
transvaginal ultrasound scan two weeks later.
Assessment of follicular growth and endometrial thick-
ness by ultrasound scan as well as oocyte collection were
performed by the same fertility specialist being unaware
of the study group in which the patient was assigned. Sim-
ilarly, evaluation of oocyte maturation, ICSI procedure
and embryo quality assessment were performed by a
unique embryologist who was blinded too.
Study endpoints
The primary aim of this study was to assess the effect of
short-term pre-rFSH administration of hCG in women
entering an ICSI treatment cycle on follicular develop-
ment, quality of oocytes and early embryo development.
To this end, ovarian ultrasound profile, serum estradiol
level on day 5 of rFSH administration, serum E2 level and
E2 level per follicle on the day of triggering ovulation,
number of oocytes collected and oocyte maturation rate
were recorded. The secondary endpoints were the meas-
urement of the effects on endometrial quality (endome-
trial thickness>8 mm) and on ICSI outcome expressed by
fertilizationand pregnancy rates.
Statistical evaluation
ANOVA models were used to detect a group or treatment
effect. Tests of normality and equality of variance of the
residuals were applied for validation of the model. Esti-
mates, P values and 95% confidence intervals (CIs) of the
difference between groups and/or treatments were com-
puted. For efficacy parameters for which several measure-
ments were obtained on the same patient (i.e. oocyte
nuclear maturity, grading of embryos), a generalized
mixed linear model was applied. For proportions (i.e.
pregnancies), a logistic regression model was used. LogReproductive Biology and Endocrinology 2009, 7:91 http://www.rbej.com/content/7/1/91
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odds ratios, P values and 95% CIs of the log of the odds
ratio between groups and treatments were computed. Lab-
oratory and safety measures, unless otherwise noted, were
analyzed using the same statistical tests.
Results
All 50 patients that were initially included in this pilot
study were randomized into two groups: Group 1 (long
protocol with rFSH) consisted of 28 patients and Group 2
(long protocol with rFSH + 7 days hCG) consisted of 22
patients. Four patients (one from Group 1 and three from
Group 2) dropped-out of the study before ovulation
induction for personal reasons. All patients were pre-men-
opausal, aged 25-39 years (median age: 33 years) and had
a normal hormonal profile. The indication for ICSI was
male infertility, but in a minor subset of the patients,
equally distributed between the two study groups, one or
more of the following co-existing causes of infertility were
present: tubal factor, anovulation and endometriosis. The
patients' demographic characteristics and hormonal pro-
files were similar in both groups (Table 1).
All the patients had menstruated before starting either
FSH or hCG administration. Ovarian response in both
groups is presented in Table 2. The duration of ovarian
stimulation, as well as the total dose of gonadotrophins,
were similar in both groups. Patients in the two groups
did not show any significant difference in their E2 levels
on day 5 of rFSH administration (259.3 ± 175.8 pg/ml in
Group 1 vs. 305 ± 214.4 pg/ml in Group 2 p > 0.05), but
those in Group 2 showed higher serum E2 levels on the
day of hCG administration (ovulation induction)
(1,643.5 ± 800.2 pg/ml in Group 1 vs. 2,125 ± 1,190.2 pg/
ml in Group 2 p < 0.05). Serum E2 levels per follicle on the
day of hCG administration tended to be higher in Group
2, but not significantly different (200 ± 98.9 pg/ml in
Group 1 vs. 139 ± 116.9 pg/ml in Group 2 p > 0.05).
The mean number of oocytes retrieved per patient was
comparable between the two groups (7 ± 3 in Group 1 vs.
8 ± 2 in Group 2, p > 0.05), although the percentage of
mature oocytes per retrieval per patient tended to be
higher in Group 2 (66.7% ± 17% vs. 78.9% ± 18% respec-
tively, p > 0.05). The number of fertilizable oocytes
obtained was not significantly different between the two
groups (5 ± 2 vs. 6 ± 2 respectively, p > 0.05), such as the
fertilization rate (87.5% ± 12.5% vs. 85% ± 15% respec-
tively, p > 0.05). In addition, the percentage of women
that had more than one grade 3 embryos in Group 1 was
significantly lower compared to that in Group 2 (women
with grade 3 embryos: 47.6% in Group 1 vs. 85.3% in
Group 2 p < 0.05). Similarly, patients that were included
in the hCG pre-treatment group (Group 2) showed a sig-
nificantly better endrometrial quality assessed by
endometrial proliferation on the ultrasound scan
(endometrial thickness > 8 mm) during embryo transfer
(46.4% in Group 1 vs. 61.3% in Group 2, p < 0.05).
Finally, pregnancy rate (PR) in Group 1 was 31.8%, com-
pared to 46.2% in Group 2 (p < 0.05).
Discussion
The identical alpha subunit and the significant sequence
homology of beta subunit between LH and hCG, results
in the exertion of both hormones' activity through the
same receptor, LH/hCGR. However, hCG has a longer
half-life and is much more potent than LH [30]. The long-
acting profile of hCG renders this compound more attrac-
tive in terms of LH activity, as it can provide more pro-
longed and stable stimulation of LH/hCG receptors than
rLH in between daily hormone administrations [19].
Although LH activity in COH is feasible with the adminis-
tration of rLH, hMG or hCG, relatively few data exist
regarding the use of hCG.
Daily doses of 50-200 IU of hCG have been used to sup-
plement FSH in COH or even substitute FSH in the late
follicular phase, so far [19-22]. A single dose of 1250 IU
was implemented in a GnRH-antagonist protocol in com-
bination with aromatase inhibitor in early-follicular-
phase [21]. A fixed 7 days pre-treatment with 300 IU rLH
in a long GnRH-a protocol was conducted recently [7]. We
opted 200 IU hCG daily dose, the maximum dose ever
Table 1: Patients' demographic mean characteristics and hormonal profiles based on the administered treatment.
Group 1 (r-FSH)
n = 27
Group 2 (r-FSH+hCG)
n = 19
Age (years) 33 ± 4 34 ± 4
Duration of infertility (years) 6 ± 4 6 ± 2
Previous attempts 1 ± 0 1 ± 1
Weight (Kgs) 59 ± 13 64 ± 10
Height (cm) 162 ± 8 168 ± 5
BMI 22.5 ± 5.2 23 ± 4.4
FSH (mlU/ml) 7.5 ± 3.2 6.7 ± 1.2
LH (mlU/ml) 5.2 ± 1.8 4.6 ± 3.1
PRL (mg/ml) 13.9 ± 5.8 14.4 ± 5.3Reproductive Biology and Endocrinology 2009, 7:91 http://www.rbej.com/content/7/1/91
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used in relevant studies, because we designed to start hCG
as soon as pituitary desensitization had occurred prior
and not concurrently with rFSH administration. Given
that LH/hCG receptors are present only on theca and not
granulosa cells by that time, we did not decide on a higher
dose to avoid possible side effects of excessive androgen
production, which may compromise follicular potential.
Concerning the timing of hCG administration, we
assumed that pre-treatment instead of combining hCG
with rFSH would have a better effect on follicular respon-
siveness to FSH as discussed below.
It is well known that follicular development is highly
dependent on pituitary secretion of FSH and LH. These
hormones are essential for normal follicular E2 produc-
tion, an action presented in the literature as the two-cell
two-gonadotrophin theory [31,32]. In fact, LH induces
androgen production by the theca cells, whereas FSH pro-
motes aromatase enzyme expression and thus the utility
of androgens as a substrate for estrogen biosynthesis.
Moreover, it has been shown that androgens themselves
promote aromatase activity [2]. Thus, it could be specu-
lated that LH-mediated androgen production increases
follicular responsiveness to FSH [7]. In this context, Durn-
erin et al found that a fixed 7 days treatment with rLH
prior to rFSH administration in a long GnRH-a protocol
increased the number of small antral follicles prior to FSH
stimulation and yielded an increased number of normally
fertilized embryos [7]. In line with these data, our study
showed that the percentage of patients with more than
one grade 3 embryos was higher in the hCG pre-treatment
group. Furthermore, that group had also a higher preg-
nancy rate. A recent study, in which hCG was adminis-
tered as a single dose in combination with aromatase
inhibitor in early-follicular-phase GnRH-antagonist pro-
tocol, resulted in increased number of good quality
embryos. However, pregnancy rate did not differ between
the study groups and implantation rate was significantly
lower in the hCG group. Possible explanations for the dif-
ferent "hCG priming" effect on pregnancy rate in compar-
ison to our results, and furthermore, the lower
implantation rate observed in hCG-treated patients, could
be the application of GnRH-antagonist instead of agonist
protocol, which would have affected the quality of the
endometrium [33] and aromatase inhibitor which is
known to interfere in the process of steroidogenesis
decreasing estrogen production and thus endometrial
proliferation [34].
GnRH agonists are mainly characterized by their pituitary
desensitization effect. However, they are also known to
cause an early receptor activation leading to a flare up
effect. This effect may be crucial for follicular recruitment,
especially in the early stages of the maturation process.
Several studies support this hypothesis, since discontinu-
ing the GnRH agonist after five days of administration
resulted to a recondite fall of LH levels in comparison to
an unceasing administration [35]. In addition to the
amount and duration of GnRH agonist treatment, a recent
study has shown that ovarian response and pregnancy
rates correlated to the route of administration [36]. In our
study, intranasal buserelin resulted in significantly less
depressed mid-follicular LH levels and increased preg-
nancy rates. This observation can reason for the variability
in the treatment outcome of otherwise similar protocols
that used s.c. administration. Furthermore, it may explain
the differences in residual LH levels reported by previous
studies [10,37-39].
Our study shows that hCG pre-treated women tended to
have higher E2 levels on the day of hCG administration for
triggering ovulation and resumption of meiotic division,
which have been suggested to be related to better quality
embryos and increased pregnancy rates. Actually, this was
also the fact in our study. A possible explanation could be
the direct induction of theca cells androgen production
which is subsequently transformed to estrogen in granu-
losa cells through an increased aromatization rate.
Table 2: Patients' ovarian response based on the administered treatment (mean values, * = p < 0.05). 
Group 1 (r-FSH)
n = 27
Group 2 (r-FSH+hCG)
n = 19
E2 on day 5 of FSH admin. 259.3 ± 175.8 220 ± 214.4
E2 on day of hCG admin. 1643.5 ± 800.2 2125* ± 1190
E2/follicle on day of hCG admin. 200 ± 98.9 239 ± 116.9
No. of follicles 8 ± 3 10 ± 3
No. of oocytes 7 ± 3 8 ± 2
Mature oocytes (%) 66.7 ± 17 78.9 ± 18
Fertilized oocytes (%) 87.5 ± 12.5 85 ± 15
Embryo quality (%) 47.6 85.3*
Endometrial quality (%) 46.4 61.3*
Pregnancy Rate (%) 31.8 46.2*
Embryo quality is defined as patients with more than one Grade 3 embryos; Endometrial quality is defined as patients with endometrial thickness ≥ 
8 mm.Reproductive Biology and Endocrinology 2009, 7:91 http://www.rbej.com/content/7/1/91
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We also found a beneficial effect of hCG pre-treatment on
endometrial quality defined as endometrial thickness >8
mm, assessed by ultrasound scan on the day of egg collec-
tion. In fact, the thickness of the endometrium on the day
of oocyte retrieval was statistically higher in the hCG
group (>8 mm, 61.3% vs. 46.4 in Group 1, p < 0.05). This
feature was related to a tendency for a higher pregnancy
rate compared to the control group. Increased endome-
trial thickness could be attributed to enhanced estrogen
production. However, Fillicori et al. have shown that hCG
has the potential to improve uterine receptivity by
enhancing endometrial quality and stromal fibroblast
function [40]. In fact, through its mechanism that
involves insulin-like growth factor binding protein-1
(IGF-1) and vascular endothelial growth factor (VEGF),
hCG probably stimulates endometrial angiogenesis and
extends the implantation window. This could explain the
more efficient implantation rate in patients that received
adjuvant treatment with hCG in our study. This observa-
tion suggested for the first time that pre-treatment with
hCG may lead to an improved endometrial receptivity
profile. It could be postulated that early hCG administra-
tion ameliorates the receptivity of the endometrium by
enhancing endometrial environment and stromal fibrob-
last function [41,42].
Several studies support the implication of LH/hCG activ-
ity during early luteal phase in endometrial preparation
for implantation [43,44]. On the other hand, comparably
few data exist regarding the potential effects of hCG dur-
ing early follicular phase on the functional maturation of
endometrium. It is well known that under physiologic
conditions, hCG is not present during this period. How-
ever, preovulatory endometrium is variably exposed to
this hormone in all COH protocols that use HMG or puri-
fied gonadotrophins. The main exposure occurs at the end
of the stimulation process, when the ovulation-triggering
dose of hCG is administered.
Current evidence implies that simply raising the daily
dose of rFSH only partially compensates for the ovaries
which are resistant to gonadotrophins. On the other
hand, soon after preantral-antral follicle transition, gran-
ulosa cells develop LH receptors, hence becoming sensi-
tive to LH as well as hCG stimulation. Besides, LH or hCG-
mediated theca cell androgen production has been sug-
gested to increase follicular responsiveness to FSH. Thus,
it could be hypothesized that granulosa cells resistant to
rFSH stimulation might benefit from low dose hCG
administration during the early follicular phase.
Conclusion
In summary, all these clinical data suggest a point towards
a beneficial "hCG priming" effect particularly in patients
with previous IVF/ICSI failures. However, larger scale
studies targeted in ovarian dysfunction patients are
needed to elucidate a potential role for hCG pre-treatment
in this poorly responding infertile subpopulation.
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